Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5260297 | 0.91 | KDM4D (0.33) | KDM4DKDM1AMAOBF2RKDM4E | |
| SCHEMBL5636179 | 0.91 | KDM4D (0.33) | KDM4DKDM1AMAOBF2RKDM4E | |
| SCHEMBL5636825 | 0.86 | JAK1 (0.40) | KDM4DKDM1AMAOBJAK2JAK1 | |
| SCHEMBL3577441 | 0.79 | ALDH1A1 (0.35) | KDM1AMAOBKDM4EALDH1A1HPGD | |
| SCHEMBL5530322 | 0.79 | ACACB (0.40) | KDM4ETDP1 | |
| SCHEMBL633008 | 0.76 | USP30 (0.42) | KDM4EPDE10A | |
| SCHEMBL5739690 | 0.73 | NFKB1 (0.33) | KDM4DKDM4EJAK2JAK1TDP1 | |
| SCHEMBL3577402 | 0.71 | KCNH2 (0.47) | — | |
| SCHEMBL5517577 | 0.69 | KDM4E (0.40) | KDM4E | |
| SCHEMBL3586182 | 0.69 | MAPT (0.39) | KDM1AMAOBF2RKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081650-A1 | Antimicrobial Compounds | AXTEN JEFFREY MICHAEL | 2010-04-01 | — | — | US | disclosed |
| US-7622481-B2 | Antibacterial compounds | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1537123-B1 | AMINO-SUBSTITUTED CYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS | GLAXO GROUP LTD (GB) | 2009-04-29 | — | — | EP | disclosed |
| US-20060189604-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189604-A1 | Compounds | ELANE, PIGS, SDHA | KDM4D 3745/4885SSTR4 3134/4885KDM1A 4262/4885 |
| US-20100081650-A1 | Antimicrobial Compounds | ELANE, NISCH, PIGS | KDM4D 4463/4885SSTR4 3882/4885KDM1A 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.